Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Sparrow Pharmaceuticals Presents New Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the 24th European Congress of Endocrinology


Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of glucocorticoid excess, today presented new pharmacological data during a poster session and a Rapid Communications session titled, "HPA axis modulation by a potent inhibitor indicates 11?-hydroxysteroid dehydrogenase type 1 (HSD-1) is a main source of cortisol that can bind intracellular receptors" at the 24th European Congress of Endocrinology (ECE 2022). Sparrow scientists examined the steroid hormone changes after administration of its lead therapeutic candidate, SPI-62, an HSD-1 inhibitor, to healthy adults.

"Normalized urinary free cortisol, or UFC, is a standard therapeutic target for patients with Cushing's syndrome," said David A. Katz, Ph.D., CSO at Sparrow Pharmaceuticals, "But that biomarker doesn't measure the cortisol that can access intracellular receptors and cause symptoms. UFC normalization has been shown not to correlate with clinical endpoints in patients with Cushing's syndrome. Many patients with autonomous cortisol secretion have normal UFC, yet substantial cortisol morbidity. As we conduct clinical trials for patients with those diseases, we're in search of better ways to measure the cortisol that makes patients ill."

The study analyzed historical clinical trial data to better characterize how SPI-62 impacts cortisol levels and the body's homeostatic response to those changes.

Conclusions of the study include:

HSD-1 converts cortisone to cortisol in tissues in which cortisol excess is associated with morbidity including liver, adipose, bone, and brain. SPI-62 is a potent HSD-1 inhibitor in clinical development for treatment of Cushing's syndrome and autonomous cortisol secretion, and as adjunctive therapy to prednisolone in polymyalgia rheumatica. In Phase 1 clinical trials SPI-62 was generally well tolerated and associated with maximal liver and brain HSD-1 inhibition.

To register and view the abstracts, visit ECE's website here.

To learn more about Sparrow Pharmaceuticals and its clinical pipeline, visit the website at www.sparrowpharma.com.

About Sparrow Pharmaceuticals

Sparrow Pharmaceuticals was founded to spare patients the ravages of steroids. Leveraging underappreciated scientific insights into corticosteroid biology, the company is working to provide better treatment options for serious disorders of hypercortisolism, and to revolutionize the treatment of autoimmune and inflammatory conditions. Its lead product, SPI-62, is an oral, small molecule, novel therapeutic treatment designed to target the source of active intracellular corticosteroids in key tissues.


These press releases may also interest you

at 06:25
The "3D Cell Culture Technologies Global Market Report 2022, By Type, By End Users, By Scaffold-based, By Scaffold-free, By Application" report has been added to ResearchAndMarkets.com's offering. The global 3D cell culture technologies market is...

at 06:15
The "US Indoor Air Quality Monitor Market (2022-2027) by Product, Pollutant Type, End-Use Application, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering. The US Indoor Air...

at 06:13
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has been selected for a "Top Innovation in Wound Care 2022" Award from Wound Management &...

at 06:05
QIAGEN N.V. announced its plans to release results for the second quarter of 2022. Press release date / time: Wednesday, July 27, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Thursday,...

at 06:00
Allelica, a leading genomic software company specializing in secure and scalable solutions to implement clinical-grade PRS, has published a health economics study in the Journal of the American Heart Association. The study's authors...

at 06:00
DailyBreath, LLC, a cloud-based SAAS company delivering personalized environmental insights for better asthma outcomes, announces its mobile app, DailyBreath, has been spotlighted in the #WeArePlay campaign featuring stories of people building apps...



News published on 24 may 2022 at 07:25 and distributed by: